-
Achieved record fourth quarter revenue of $11.3 million, representing 37% year-over-year growth and the 13th consecutive quarter of meeting or exceeding expectations.
-
Performance was driven by a record 16 system placements in Q4, including a major global rollout with Amgen across North America, Europe, and Asia.
-
Samsung Biologics is expanding its Growth Direct deployment with a new multisystem order in Q1 2026, validating the platform’s role in next-generation manufacturing.
-
Consumable revenue grew 17% for the full year, serving as a key indicator of active system utilization and realized ROI within the installed base.
-
Total gross margin has improved by over 50 percentage points over the last three years, supported by ongoing manufacturing efficiencies and service productivity.
-
The MilliporeSigma partnership is entering its second year with established demo labs in Europe and Asia to accelerate the global sales funnel.
-
Market tailwinds include increased regulatory focus on data integrity, pharmaceutical onshoring in the U.S., and the adoption of full automation in quality control.
-
Initiated 2026 revenue guidance of $37 million to $41 million, assuming 30 to 38 system placements with a heavy weighting toward the second half of the year.
-
Expect to achieve approximately 20% full-year gross margin, with performance accelerating to a mid-20% exit rate by Q4 2026.
-
Guidance assumes meaningful contributions from MilliporeSigma, though the low end accounts for potential timing shifts of their 2-system commitment into early 2027.
-
Planned launch of a next-generation cloud-native software platform in the second half of 2026 to leverage 15 years of AI-driven microbial growth detection data.
-
Anticipate completing at least 25 system validations in 2026, which will drive higher-margin service revenue in the latter half of the year.
-
Q4 product margins were impacted by a $1.1 million write-off of unusable consumable inventory; management stated the underlying issue has been resolved.
-
Service margins experienced temporary compression due to lower validation volumes in Q4 compared to a record-setting prior year period.
-
Locked-in contractual agreements for material cost reductions are expected to turn consumable gross margins positive in the second half of 2026.
-
The company maintains $39 million in cash and $25 million in unused debt capacity to fund strategic growth through 2026.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
